NCT03626688已完成3 期
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAH
United Therapeutics363 个研究点 分布在 2 个国家目标入组 687 人开始时间: 2019年1月24日最近更新:
适应症
干预措施
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 687
- 试验地点
- 363
- 主要终点
- Time from randomization to the first adjudicated protocol-defined clinical worsening event
研究概览
简要总结
Study ROR-PH-301, ADVANCE OUTCOMES, is designed to assess the efficacy and safety of ralinepag when added to pulmonary arterial hypertension (PAH) standard of care or PAH-specific background therapy in subjects with World Health Organization (WHO) Group 1 PAH.
详细描述
Study ROR-PH-301 is a multicenter, randomized, double-blind, placebo-controlled study. Subjects who meet entry criteria will be randomly allocated 1:1 to receive ralinepag or placebo, in addition to their standard of care or PAH-specific background therapy, as applicable. The primary endpoint is the time (in days) from randomization to the first adjudicated protocol-defined clinical worsening event. All primary endpoint events will be adjudicated by an independent Clinical Event Committee (CEC) in a blinded fashion. Subjects who have a confirmed primary endpoint event adjudicated by the CEC at any time during the study and all subjects on treatment at the conclusion of the study who have completed the Week 28 Visit (after the target number of confirmed events is achieved) will have the option to enroll in an open-label extension (OLE) study. Subjects who do not choose to participate in the OLE study will discontinue study drug and should remain in the study for long-term follow-up of survival status and will receive standard of care PAH treatment, at the discretion of the treating physician.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •At least 18 years of age.
- •Evidence of a personally signed and dated informed consent form indicating that the subject has been informed of all pertinent aspects of the study prior to initiation of any study-related procedures.
- •Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures
- •Primary diagnosis of symptomatic PAH.
- •Has had a right heart catheterization (RHC) performed at or within 3 years prior to Screening (RHC will be performed during Screening if not available) that is consistent with the diagnosis of PAH.
- •Has WHO/ NYHA functional class II to IV symptoms.
- •If on PAH-specific background oral therapy, subject is on stable therapy with either an endothelin receptor antagonist (ERA) and/or a phosphodiesterase type 5 inhibitor (PDE5-I) or a soluble guanylate cyclase (sGC) stimulator.
- •Has a 6MWD of ≥150 meters.
- •If taking concomitant medications that may affect the clinical manifestations of PAH (eg, calcium channel blockers, diuretics, digoxin, or L arginine supplementation, beta blockers, angiotensin-converting enzyme inhibitors, or angiotensin II receptor blockers), must be on a stable dose for at least 30 days prior to the Baseline Visit and the dosage maintained throughout the study. The exception is that the dose of diuretics must be stable for at least the 10 days prior to Baseline.
- •Both male and female subjects agree to use a highly effective method of birth control throughout the entire study period from informed consent through to the 30-Day Follow-up Visit, if the possibility of conception exists. Eligible male and female subjects must also agree not to participate in a conception process during the study and for 30 days after the last dose of IMP. Eligible male subjects must agree not to participate in sperm donation for 90 days after the last dose of IMP.
排除标准
- •For subjects with known HIV-associated PAH, a cluster designation 4 (CD4+) T-cell count <200/mm3 within 90 days of Baseline.
- •Must not have 3 or more left ventricular dysfunction risk factors as defined in the study protocol.
- •Has evidence of more than mild lung disease on pulmonary function tests performed within 180 days prior to, or during Screening.
- •Has evidence of thromboembolic disease as determined by a V/Q lung scan or local standard of care diagnostic evaluation at or after diagnosis of PAH.
- •Current diagnosis of ongoing and clinically significant sleep apnea as defined by the Investigator.
- •Male subjects with a corrected QT interval using Fridericia's formula (QTcF) >450 msec and female subjects with a QTcF >470 msec on ECG recorded at Screening and analyzed by the central ECG laboratory. Subjects with evidence of intraventricular conduction delay, defined as a QRS interval greater than 110 msec, will be excluded if the QTcF is >500 msec for both males and females.
- •Severe chronic liver disease (ie, Child-Pugh Class C), portal hypertension, cirrhosis or complications of cirrhosis/portal hypertension (eg, history of variceal hemorrhage, encephalopathy).
- •Confirmed active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV).
- •Subjects with alanine aminotransferase or aspartate aminotransferase ≥3 times the upper limit of normal (ULN) or total bilirubin ≥2 × ULN at Screening.
- •Chronic renal insufficiency as defined by serum creatinine >2.5 mg/dL or requiring dialysis at Screening.
- •Hemoglobin concentration <9 g/dL at Screening.
- •Subjects treated with an IV or SC prostacyclin pathway agent (eg, epoprostenol, treprostinil, or iloprost) or activin signaling inhibitor for PAH at any time prior to Baseline (use in vasoreactive testing is permitted).
- •Subjects currently on or who were treated with an inhaled or oral prostacyclin pathway agent (iloprost, treprostinil, beraprost, or selexipag) for >6 months or within 90 days prior to Baseline.
- •Subject has pulmonary veno-occlusive disease.
- •Malignancy diagnosed and/or treated within 5 years prior to Screening, with the exception of localized non-metastatic basal cell or squamous cell carcinoma of the skin or in-situ carcinoma of the cervix excised with curative intent.
- •Subject tests positive for amphetamine, cocaine, methamphetamine, methylenedioxymethamphetamine or phencyclidine in urine drug screen performed at Screening, or has a recent history (6 months) of alcohol or drug abuse. A subject will not be excluded due to a positive drug screen caused by prescribed medications.
- •Initiation or discontinuation of a cardio-pulmonary rehabilitation program based upon exercise within 90 days prior to Screening and/or planned during study participation.
- •Prior participation in any study of ralinepag or participation in another interventional clinical study with medicinal products within 30 days prior to Screening. Concurrent participation in registry or observational studies is allowed, as long as the subject can fulfill all other entry criteria and comply with all study procedures.
- •Any reason that, in the opinion of the Investigator or Medical Monitor, precludes the subject from participating in the study (eg, any previous or intercurrent medical condition) that may increase the risk associated with study participation or that would confound study analysis or impair study participation or cooperation.
- •Known hypersensitivity to ralinepag or any of the excipients.
- •Life expectancy <12 months based on the Investigator's opinion.
- •Women who are pregnant, lactating or breast-feeding.
研究组 & 干预措施
Placebo
Placebo Comparator
Matching placebo tablets (oral)
干预措施: Placebo (Drug)
Ralinepag
Experimental
Ralinepag once daily extended-release tablets (oral) 50, 250, and 400 mcg titrated to the highest tolerated dose.
干预措施: Ralinepag (Drug)
结局指标
主要结局
Time from randomization to the first adjudicated protocol-defined clinical worsening event
时间窗: The study duration was event-based. This parameter was assessed from randomization until the conclusion of the study, up to 3 years
Clinical worsening events are defined as death, nonelective hospital admission for worsening PAH (further defined in clinical study protocol), initiation of parenteral or inhaled prostacyclin pathway agent for treatment of worsening PAH, disease progression (further defined in clinical study protocol), or unsatisfactory long-term clinical response (further defined in clinical study protocol).
次要结局
- Change from Baseline in 6-minute walk distance (6MWD)(Baseline to Week 28)
- Registry to Evaluate Early and Long-term PAH Disease Management (REVEAL) risk score(Baseline to Week 28)
- Time to first all-cause nonelective hospitalization(The study duration was event-based. This parameter was assessed from randomization until the conclusion of the study (when the target number of adjudicated events was achieved, as defined in the study protocol).)
- Change from Baseline in N-terminal pro-brain natriuretic peptide (NT-proBNP)(Baseline to Week 28)
- Change from Baseline in WHO/New York Heart Association (NYHA) Functional Class(Baseline to Week 28)
- Shift and proportion of subjects who attain all 3 of the following: NT-proBNP level <300 pg/mL, 6MWD >440 meters, and WHO/NYHA Functional Class I or II(Baseline to Week 28)
- Clinical improvement as defined by the absence of clinical worsening and fulfillment of at least 2 of the 3 of the following: increase in 6MWD ≥10% or ≥30 m, improvement to or maintenance of WHO FC I or II, and decrease in NT-proBNP by at least 30%.(Baseline to Week 28)
- Safety and tolerability of ralinepag in subjects with PAH(Baseline to Week 28)
- Change from Baseline in health-related quality of life as measured by patient-reported outcomes.(Baseline to Week 28)
- Time to all-cause mortality(The study duration was event-based. This parameter was assessed from randomization until the conclusion of the study (when the target number of adjudicated events was achieved, as defined in the study protocol).)
- Change from Baseline in heart rate recovery (HRR) following completion of the 6MWT(Baseline to Week 28)
研究者
研究点 (363)
Loading locations...
相似试验
终止
3 期
Study of Ralinepag on Exercise Capacity by Cardiopulmonary Exercise Testing (CPET) in WHO Group 1 PH SubjectsConnective Tissue DiseaseFamilial Primary Pulmonary HypertensionVascular DiseasesCardiovascular DiseasesHypertension, PulmonaryLung DiseasesRespiratory Tract DiseasePulmonary Arterial HypertensionPulmonary HypertensionHypertensionPAHNCT04084678United Therapeutics10
已完成
3 期
Efficacy and Safety of Adult Human Mesenchymal Stem Cells to Treat Steroid Refractory Acute Graft Versus Host Disease (GVHD)Graft Versus Host DiseaseNCT00366145Mesoblast, Inc.260
招募中
3 期
ICP-332 in Subjects With Moderate to Severe Atopic DermatitisAtopic DermatitisNCT06775860Beijing InnoCare Pharma Tech Co., Ltd.552
已完成
3 期
Efficacy and Safety of Odevixibat in Patients With Alagille SyndromeAlagille SyndromeNCT04674761Albireo52
招募中
3 期
Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Chronic Primary Immune ThrombocytopeniaChronic Primary Immune Thrombocytopenia (ITP)NCT06004856Beijing InnoCare Pharma Tech Co., Ltd.195